Treats Attention-Deficit/Hyperactivity Disorder (ADHD). ANDA 79016, held by Aurobindo Pharma. Atomoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 79016 (Atomoxetine Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on May 30, 2017, with 3 approved supplements and 0 published complete response letters.
Atomoxetine capsules are a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). 1.1 Attention-Deficit/Hyperactivity Disorder (ADHD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 30, 2017 | Original application | Approved |
| Atomoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 18MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 25MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 60MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 80MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 100MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Nov 2, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 20, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 20, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 30, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters